Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:

NCT ID: NCT04927156 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

Start date: June 2021
Phase:
Study type: Observational

BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices. This platform is purely exploratory, without hierarchical order of the objectives and associated outcomes.

NCT ID: NCT04918719 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

Stroke is a major cause of death and long-term disability in the developed world. While t-PA and mechanical thrombectomy have been shown to decrease disability in properly selected patients, many patients are left with lifelong symptoms. There are currently limited options available for patients who are not candidates for treatment with t-PA and/or mechanical thrombectomy. N-Acetylcysteine (NAC) is an FDA approved antioxidant and anti-inflammatory agent that has been used safely for many years in the treatment of acetaminophen overdose. In studies, the oral form has been shown to improve outcomes in acute ischemic stroke and has been shown to decrease the effects of ischemic brain injury in animal models. In a small human trial, it improved outcomes in patients suffering from mild traumatic brain injury (TBI). The intravenous formulation has a long safety record. It is not FDA approved for treating stroke but was reviewed by the FDA and was given an FDA IND for this study. The investigators propose a prospective randomized, double-blind, placebo-controlled study to evaluate the efficacy of administering intravenous N-acetylcysteine to patients with acute ischemic stroke. Eligible subjects will receive a commercially available form of intravenous NAC (Acetadote®) through for the first 21 hours following their enrollment. Patients enrolled who receive t-PA for thrombolysis will have their intravenous NAC infusion delayed for 24 hours after the completion of their t-PA infusion. Patients undergoing thrombectomy will be excluded from enrollment. Subjects will be evaluated by emergency department and/or division of neurology physicians at the time of enrollment, during their hospitalization, as well as 30 days and 90 days after enrollment. At each visit, subjects will be assessed for functional status and quality of life. This study is designed to compare the efficacy of intravenous N-acetylcysteine compared to normal treatment in patients with acute ischemic stroke.

NCT ID: NCT04916782 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Evaluation of Functional Recovery of Patients With Acute Ischemic Stroke Treated by Thrombectomy

EPIC
Start date: June 2021
Phase:
Study type: Observational

The management of cerebral infarctions (CI) is a real public health issue. The French National Authority for Health recommends Mechanical Thrombectomy (MT) either in combination with Intravenous Thrombolysis (IVT), or alone, after failure of IVT or in case of contraindication to IVT, within 6 hours of the onset of symptoms. The objective is to determine the factors predicting good functional recovery at 3 months in order to establish the typical profile of the "good responder" patient to MT and to evaluate functional recovery at 3 and 12 months (mRS ≤ 2) according to the modality of MT (depending on whether it is performed during the day or at night), the age of the patients, the equipment used for MT, the type of anaesthesia, as well as the impact of the metrics from the radiological evaluation in the patient's management. patient management.

NCT ID: NCT04916197 Recruiting - Clinical trials for Acute Ischemic Stroke

Effect of Prolonged Sedation With Dexmedetomidine on Long-term Prognosis of Patients With Acute Ischemic Stroke After Mechanical Thrombectomy

Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Dexmedetomidine can attenuate the activity of sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after thrombectomy may improve the clinical outcome of acute ischemic stroke patients.

NCT ID: NCT04892511 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

A Trial on Hemodynamic Optimization of Cerebral Perfusion After Endovascular Therapy in Patients With Acute Ischemic Stroke

HOPE
Start date: June 1, 2021
Phase: Phase 4
Study type: Interventional

Mechanical thrombectomy is a very effective treatment in patients who have suffered an acute ischemic stroke associated with intracranial large vessel occlusion. However, less than half of the patients achieve functional independence despite treatment. The optimization of blood pressure after mechanical thrombectomy based on the degree of recanalization achieved at the end of the procedure could improve the perfusion of the ischemic brain tissue thanks to the improvement of blood circulation provided by collateral circulation. For this, authorized hypotensive or hypertensive drugs will be used. Moreover, this individualized treatment would allow to decrease reperfusion injury and therefore decrease the risk of intracerebral bleeding complications and cerebral edema. Therefore, we designed a clinical trial in which the standard management of blood pressure after mechanical thrombectomy will be compared with a specific protocol in which blood pressure targets are applied according to the degree of recanalization obtained during the thrombectomy procedure. The beneficial effect and risk reduction of this treatment will translate into a better short and long-term outcome

NCT ID: NCT04891913 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

SY007 in Patients With Acute Ischemic Stroke

Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be evaluated and this study will provide the recommended dosage for subsequent clinical trials.

NCT ID: NCT04891497 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with intraarterial treatment in patients with Acute Ischemic Stroke.

NCT ID: NCT04890366 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke.

NCT ID: NCT04890353 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in in alleviating neurologic deficits in patients with Acute Ischemic Stroke.

NCT ID: NCT04881162 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System

NITE1
Start date: September 2021
Phase: N/A
Study type: Interventional

Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions.